John Murphy

John Murphy

Auto-generated profile, based on publicly available information

John Murphy

Real World Research, Ontada, Boston, MA, United States

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2023 in The Breast
Verified
Journal Article
Open access
AAA. Agrawal
A. Agrawal
LRL. Romics
L. Romics
DTDinesh Kumar Thekkinkattil
Dinesh Kumar Thekkinkattil
MSM. Soliman
M. Soliman
MKMonika Kaushik
Monika Kaushik
AHAhmed Hamad
Ahmed Hamad
Partial breast reconstruction with a pedicled chest wall perforator flap (CWPF) enables breast conservation in a higher tumour: breast volume ratio scenario. Since there is limited evidence, this retrospective cohort study aimed to ascertain immediate (30-days) and medium-term (follow-up duration) surgical outcomes. STROBE-compliant protocol ascertained CWPF outcomes between March 2011-March 2021. UK centres known to perform CWPF were invited to participate if they performed at least 10 cases. Data were retrospectively collected, including patient demographics, tumour and treatment characteristics, and surgical and oncological outcomes. Statistical analysis (R™) included multivariable logistic regression and sensitivity analysis. Across 15 centres, 507 patients with median age (54 years, IQR; 48-62), body mass index (25.4 kg/m2, IQR; 22.5-29), tumour size (26 mm, IQR; 18-35), and specimen weight (62 g, IQR; 40-92) had following flap types: LiCAP (54.1%, n = 273), MiCAP/AiCAP (19.6%, n = 99), LiCAP + LTAP (19.8%, n = 100) and TDAP (2.2%, n = 11). 30-days complication rates were in 12%: haematoma (4.3%, n = 22), wound infection (4.3%, n = 22), delayed wound healing (2.8%, n = 14) and flap loss (0.6%, n = 3; 1 full) leading to readmissions (2.6%, n = 13) and re-operations (2.6%, n = 13). Positive margins (n = 88, 17.7%) led to 15.9% (n = 79) re-excisions, including 7.5% (n = 37) at the planned 2nd of 2-stage surgery and 1.8% (n = 9) mastectomy. At median 23 months (IQR; 11-39) follow-up, there were 1.2% (n = 6) symmetrisations; recurrences: local (1%), regional/nodal (0.6%) and distant (3.2%). This large multicentre cohort study demonstrates acceptable complication and margin re-excision rates. CWPF extends the range of breast conservation techniques. Further studies are required for long-term oncological outcomes.

24 February 2020 in Plastic and Reconstructive Surgery - Global Open
Verified
Journal Article
Open access
GIGareth W. PhD Irwin
Gareth W. PhD Irwin
GBGeorge PhD Boundouki
George PhD Boundouki
BFBilal MBChB Fakim
Bilal MBChB Fakim
RJRichard Frcs Johnson
Richard Frcs Johnson
LHLyndsey Highton
Lyndsey Highton
JMJohn A. PhD Murphy
John A. PhD Murphy
Background: Single-use negative pressure wound therapy (NPWT) has been shown to encourage wound healing. It is often used when patient factors impair wound healing, or in more complex wounds, such as in implant-based breast reconstruction. We report the findings of a prospective cohort study comparing the use of NPWT with standard dressings in prepectoral breast reconstruction. Methods: A prospective database of implant-based reconstruction from a single institution was mined to identify patients who underwent prepectoral reconstruction. Patient demographics, operative data, surgical complications, and 90-day outcomes were compared between patients who had NPWT and those who had standard dressings. Results: Prepectoral implant-based breast reconstruction was performed on 307 breasts. NPWT dressings were used in 126 cases, with standard dressings used in 181 cases. Wound breakdown occurred in 10 cases after standard dressings versus 1 where NPWT was utilized. Of the standard dressing cases, only 3 implants were salvaged, while 7 cases led to implant loss. The 1 case of wound breakdown in the NPWT cohort settled with conservative measures. The cost of a reconstructive failure was £14,902, and the use of NPWT resulted in a cost savings of £426 per patient. Conclusions: The utilization of single-use NPWT reduces the rate of wound breakdown and implant loss in prepectoral implant-based reconstruction. In addition to the significant clinical benefits, this approach is cost-saving compared with standard dressings. These data suggest that prepectoral implant reconstruction should be considered as an indication for the use of NPWT.

1 May 2021 in British Journal of Surgery
Verified
Journal Article
Open access
PDF file
RDRajiv `v Dave
Rajiv `v Dave
AVA Vucicevic
A Vucicevic
EBE Barrett
E Barrett
LHL Highton
L Highton
RJR Johnson
R Johnson
JMJ Murphy
J Murphy
Background: Prepectoral implant-based breast reconstruction with acellular dermal matrix has become an increasingly popular option for selected patients. There are no randomized data to demonstrate short- or long-term outcomes. Cohort studies to date have demonstrated safety, but risk factors for complications are unknown. Methods: A prospective cohort study of all patients undergoing prepectoral implant-based breast reconstruction between 2013 and 2019. Clinical factors and those related to reconstruction were analysed in relation to complications and implant loss using univariable and multivariable logistic regression. Results: A total of 469 reconstructions were undertaken in 289 women; the majority of reconstructions were performed using a one-stage direct-to-implant technique with acellular dermal matrix. Median follow-up was 21 (range 2–71) months. Minor complications were seen after 11·2 per cent of reconstructions, major complications after 5·9 per cent, and the rate of implant loss by 3 months was 3·1 per cent. In the final multivariable model, sentinel node biopsy (odds ratio (OR) 5·06, 95 per cent c.i. 2·00 to 12·80), axillary clearance (OR 6·67, 1·17 to 37·94) and adjuvant radiotherapy (OR 7·11, 1·60 to 31·61) were independent risk factors for development of a major complication, and sentinel node biopsy (OR 4·32, 1·23 to 15·22) for implant loss. Conclusion: Prepectoral implant-based breast reconstruction has acceptable medium-term results but careful patient selection is advised.

1 January 2014 in International Journal of Surgery
Verified
Journal Article
Closed access
JHJames Harvey
James Harvey
JHJulia Henderson
Julia Henderson
LPLopa Patel
Lopa Patel
JMJohn Murphy
John Murphy
RJRichard Johnson
Richard Johnson
Therapeutic mammaplasty allows breast conservation and maintains breast cosmesis in women with larger and ptotic breasts. They are associated with more post-operative complications, potentially delaying adjuvant treatment. Our aim is to investigate the impact of therapeutic mammaplasty on the timing of adjuvant chemotherapy, compared with conventional breast conservation surgery. Retrospective data collection of breast cancer patients undergoing breast-conserving surgery at a single institution from 2009 to 2013. 1000 patients underwent breast-conserving surgery, 40 underwent therapeutic mammaplasty. Patients with a complication of mammaplasty had no delay to starting chemotherapy compared to those without complication (median 36 vs. 40 days). There was no delay to chemotherapy for patients requiring further breast cancer excision surgery following therapeutic mammaplasty compared with standard breast conservation surgery (36 vs. 39 days). There is no delay in commencing adjuvant chemotherapy following therapeutic mammaplasty surgery, even if there is a complication of surgery. However, patients with involved margins had a significant delay to chemotherapy whilst awaiting re-excision surgery.

1 July 2021 in Clinical Oncology
Verified
Journal Article
Closed access
JMJ. Murphy
J. Murphy
AGA. Gandhi
A. Gandhi

17 August 2023 in Frontiers in Oncology
Verified
Journal Article
Open access
CBChristopher M. Black
Christopher M. Black
KRKarthik Ramakrishnan
Karthik Ramakrishnan
ENEric Nadler
Eric Nadler
WTWan-Yu Tseng
Wan-Yu Tseng
CWChuck Wentworth
Chuck Wentworth
GPGregory Patton
Gregory Patton
Introduction: There is a need to understand the current treatment landscape for LA HNSCC in the real-world setting.Methods: This retrospective study assessed real-world outcomes and treatment patterns of 1,158 adult patients diagnosed with locally advanced (stage III-IVB) HNSCC initiating chemoradiotherapy (CRT) within the period January 2015 to December 2017 in a large network of US community oncology practices. Structured data were abstracted from electronic health records. Demographic, clinical and treatment characteristics were analyzed descriptively overall and stratified by index treatment (cisplatin + radiotherapy [RT], cisplatin + other chemotherapy + RT, or cetuximab + RT). Time to next treatment (TTNT) and overall survival (OS) were measured using the Kaplan-Meier method, and median duration of treatment was assessed. OS was compared across treatment cohorts using multinomial logistic regression with inverse probability treatment weighting. To identify covariates associated with OS, a multivariable adjusted Cox proportional hazard model was used.Results: This study examined 22,782 records, of which 2124 had stage III to stage IVB and no other cancers, and 1158 met all eligibility criteria. Among the treatment cohorts analyzed (cisplatin + RT, cisplatin + other chemotherapy + RT, or cetuximab + RT), cisplatin + RT was the most common concurrent chemotherapy (65.8%). Among 1158 patients, 838 (72.4%) did not initiate subsequent treatment and 139 (12.0%) died. The median TTNT and median OS were only reached by the cetuximab + RT cohort. Among patients with oropharynx primary tumor location, patients with human papilloma virus (HPV) positive status had the longest time on treatment and highest survival at 60 months. Covariates associated with improved survival were never/former tobacco use, HPV positive status, and overweight or obese body mass index. Covariates associated with poorer survival were age of 60+ years, primary tumor location of hypopharynx or oral cavity and Eastern Cooperative Oncology Group performance status score of 2+.Conclusion: These data describe real-world treatment patterns in locally advanced head and neck squamous cell cancer and sets the baseline to assess outcomes for future studies on the community oncology population.